Supriya Lifescience
Supriya Lifescience Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Supriya Lifescience
Start SIPSupriya Lifescience Investment Rating
-
Master Rating:
-
Supriya Lifescience has an operating revenue of Rs. 499.94 Cr. on a trailing 12-month basis. An annual revenue growth of 36% is outstanding, Pre-tax margin of 39% is great, ROE of 24% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 58 which is a POOR score indicating inconsistency in earnings, a RS Rating of 7 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 169 indicates it belongs to a poor industry group of Medical-Supplies and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 105 | 112 | 101 | 181 |
| Operating Expenses Qtr Cr | 91 | 61 | 70 | 106 |
| Operating Profit Qtr Cr | 14 | 52 | 31 | 75 |
| Depreciation Qtr Cr | 3 | 3 | 3 | 3 |
| Interest Qtr Cr | 1 | 24 | 1 | 1 |
| Tax Qtr Cr | 3 | 11 | 5 | 29 |
| Net Profit Qtr Cr | 10 | 17 | 25 | 46 |
Supriya Lifescience Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- 200.32
- 50 Day
- 211.09
- 100 Day
- 234.21
- 200 Day
- 283.58
- 20 Day
- 201.3
- 50 Day
- 209.68
- 100 Day
- 229.02
- 200 Day
- 284.79
Supriya Lifescience Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 192.87 |
| Second Resistance | 198.74 |
| Third Resistance | 202.17 |
| RSI | 33.17 |
| MFI | 51.59 |
| MACD Single Line | -3.66 |
| MACD | -4.98 |
| Support | |
|---|---|
| First Resistance | 183.57 |
| Second Resistance | 180.14 |
| Third Resistance | 174.27 |
Supriya Lifescience Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 162,161 | 7,474,000 | 46.09 |
| Week | 191,009 | 9,120,680 | 47.75 |
| 1 Month | 203,252 | 8,164,633 | 40.17 |
| 6 Month | 244,615 | 10,197,988 | 41.69 |
Supriya Lifescience Result Highlights
Supriya Lifescience Synopsis
NSE-Medical-Supplies
Supriya Lifescience is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 530.05 Cr. and Equity Capital is Rs. 16.10 Cr. for the Year ended 31/03/2022. Supriya Lifescience Ltd. is a Public Limited Listed company incorporated on 26/03/2008 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L51900MH2008PLC180452 and registration number is 180452.| Market Cap | 1,506 |
| Sales | 500 |
| Shares in Float | 2.58 |
| No of funds | 22 |
| Yield | 0.32 |
| Book Value | 2.48 |
| U/D Vol ratio | 0.7 |
| LTDebt / Equity | |
| Alpha | -0.32 |
| Beta | 1.24 |
Supriya Lifescience
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 68.24% | 68.24% | 68.24% | |
| Mutual Funds | 2.38% | 2.38% | 3.12% | |
| Insurance Companies | 3.85% | 3.85% | 4.15% | |
| Foreign Portfolio Investors | 6.24% | 6.79% | 5.99% | |
| Individual Investors | 15.07% | 13.4% | 12.52% | |
| Others | 4.22% | 5.34% | 5.98% |
Supriya Lifescience Management
| Name | Designation |
|---|---|
| Mr. Satish Waman Wagh | Chairman & Managing Director |
| Ms. Smita Satish Wagh | Whole Time Director |
| Ms. Saloni Satish Wagh | Whole Time Director |
| Ms. Shivani Satish Wagh | Whole Time Director |
| Mr. Balasahab Gulabrao Sawant | Whole Time Director |
| Mr. Kedar Shankar Karmarkar | Independent Director |
| Mr. Bhairav Manojbhai Chokshi | Independent Director |
| Mr. Dileep Kumar Jain | Independent Director |
| Mr. Dinesh Navnitlal Modi | Independent Director |
| Ms. Neelam Yashpal Arora | Independent Director |
Supriya Lifescience Forecast
Price Estimates
Supriya Lifescience FAQs
What is Share Price of Supriya Lifescience ?
Supriya Lifescience share price is ₹187 As on 22 March, 2023 | 02:22
What is the Market Cap of Supriya Lifescience ?
The Market Cap of Supriya Lifescience is ₹1506.2 Cr As on 22 March, 2023 | 02:22
What is the P/E ratio of Supriya Lifescience ?
The P/E ratio of Supriya Lifescience is 15.4 As on 22 March, 2023 | 02:22
What is the PB ratio of Supriya Lifescience ?
The PB ratio of Supriya Lifescience is 2.4 As on 22 March, 2023 | 02:22